Bafna Pharmaceuticals Q1 FY27 Results

Revenue from operations: ₹26.58 crore (₹2658.32 lakh)
Profit for the period: ₹0.08 crore (₹7.51 lakh)

Reader Takeaway: Revenue and profit sharply down year-over-year, with significant GST litigation pending.

What just happened

Bafna Pharmaceuticals reported its financial results for the quarter ended June 30, 2026 (Q1 FY27). The company announced revenue from operations of ₹26.58 crore and a profit of ₹0.08 crore for the period.

Why this matters

The company's financial performance shows a significant decline compared to the same quarter last year. Revenue fell by 23%, and net profit saw a drastic drop of 98%. This contraction raises concerns about the company's operational efficiency and market position.

Additionally, Bafna Pharmaceuticals is involved in GST-related litigation with a total disputed liability of ₹5.67 crore, comprising a demand of ₹2.35 crore and a recovery order for ₹3.31 crore in GST refunds.

The backstory

In the previous year's corresponding quarter (Q1 FY26), Bafna Pharmaceuticals had reported revenue of ₹34.62 crore and a profit of ₹3.39 crore. The current results indicate a substantial downturn from these figures.

What changes now

Investors will be closely watching the company's future performance to see if it can reverse the trend of declining revenue and profitability. The outcome of the GST litigation could also impact the company's financial health.

Risks to watch

The primary risks include the continued decline in revenue and profit margins, and the potential financial impact if the GST litigation goes against the company, despite management's optimism.

Peer comparison

(No peer comparison data available in the filing).

Context metrics (time-bound)

• Revenue Q1 FY27: ₹26.58 crore (down from ₹34.62 crore in Q1 FY26).
• Profit Q1 FY27: ₹0.08 crore (down from ₹3.39 crore in Q1 FY26).
• GST Litigation: ₹5.67 crore.

What to track next

Investors should monitor the company's upcoming quarterly results for signs of recovery and follow developments in the GST litigation case. The date of the 31st Annual General Meeting on September 11, 2026, is also a key event to note.